FranΓ§aisπ See the interactive version (live chart) β
For ICU Medical, we replayed every analyst price target of the past 12 months and measured the real outcome: 26% were profitable, average return +6% (50 calls). At 3 months: +2% average return (41% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Raymond James | 19 | 10% | -2% |
| Keybanc | 18 | 22% | -2% |
| Piper Sandler | 5 | 60% | +23% |
The analyst consensus on ICU Medical (ICUI) is "Buy" (12 bullish, 0 bearish calls over 12 months). This is not advice: historically, 26% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $191 (+13% vs $169), ranging from $182 to $200 (4 analysts).
Over 1 year, 26% of analyst targets on ICU Medical were profitable, for an average return of +6% (across 50 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $191 within 12 months, i.e. +13% vs the current price. The most bullish targets $200, the most cautious $182.
Note: analyst targets are 12-month (median $191, +13%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (26%), and the stock's past trajectory.
Detailed valuation data for ICU Medical is available in the interactive analysis.
π See the full interactive analysis of ICU Medical β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.